Global Myocardial Infarction Drugs Market 2016-2020 - Key Vendors are Bayer HealthCare, Eli Lilly & Novartis - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/c8rjqm/global_myocardial) has announced the addition of the "Global Myocardial Infarction Drugs Market 2016-2020" report to their offering.

The global myocardial infarction drugs market is expected to grow at a CAGR of 0.41% during the period 2016-2020.

Enhanced patient awareness is expected to lead to early disease diagnosis and treatment. The World Heart Federation along with Bupa, MOVEWeek, the European Healthy Stadia Network, and Days of the Year organizes 29th September of every year as the World Heart Day. Heart Day campaigns are organized to spread awareness about heart diseases. These campaigns are sponsored by Amgen, AstraZeneca, Bupa, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Pfizer, and Unilever.

According to the report, in older people, plaque accumulation in the arteries increases because of the loss of elasticity of the blood vessels. Drugmakers are realizing that an aging population will have significant impact on their business. Increasing number of patients plus lucrative pricing equals big growth for the market.

Further, the report states that the availability of effective surgical treatments and the use of catheter-based interventions pose a challenge to the growth of the market.

Key vendors:

• AstraZeneca
• Bayer HealthCare
• Eli Lilly
• Novartis
• Pfizer
• Sanofi
  

Key questions answered in this report:

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
  

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Epidemiology and economic burden

PART 07: Pipeline analysis

PART 08: Market landscape

PART 09: Market segmentation by drug class

PART 10: Market segmentation by EKG appearance

PART 11: Market segmentation by type

PART 12: Geographical segmentation

PART 13: Market drivers

PART 14: Impact of drivers

PART 15: Market challenges

PART 16: Impact of drivers and challenges

PART 17: Market trends

PART 18: Vendor landscape

For more information visit http://www.researchandmarkets.com/research/c8rjqm/global_myocardial